Cellectar BiosciencesCLRB
About: Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
Employees: 20
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
92% more call options, than puts
Call options by funds: $138K | Put options by funds: $72K
1.38% more ownership
Funds ownership: 37.69% [Q2] → 39.07% (+1.38%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
5% less funds holding
Funds holding: 37 [Q2] → 35 (-2) [Q3]
9% less capital invested
Capital invested by funds: $33M [Q2] → $30M (-$3.08M) [Q3]
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
Research analyst outlook
We haven’t received any recent analyst ratings for CLRB.
Financial journalist opinion
Based on 3 articles about CLRB published over the past 30 days
